Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tocilizumab + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
A combination therapy consisting of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, and interferon alfa-2b, an antiviral and immunomodulatory agent. Tocilizumab is a recombinant humanized monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors, preventing IL-6 mediated inflammation. Interferon alfa-2b works through the JAK-STAT signaling pathway to induce antiviral effects and modulate immune responses. This combination has been studied in clinical trials for various conditions, including recurrent epithelial ovarian cancer.
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)IFNAR (Immune system modulation via type I interferon receptor)JAK (Janus kinase family)STAT (STAT family)
Beyond the preview
Go deeper on tocilizumab + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tocilizumab + interferon alfa-2b.